Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ) that's also probably bad news for Hims & Hers Health ( HIMS -17.80%).
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
The massive crash came after the US Food and Drug Administration (FDA) website showed the end of the shortage of Novo Nordisk ...
Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
More than 2.4 million cases of MadeGood Granola Bars have been recalled across the U.S. due to the possibility that they may ...
The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback